Rani Therapeutics Holdings, Inc. (RANI)
NASDAQ: RANI · Real-Time Price · USD
1.820
-0.270 (-12.92%)
At close: Oct 24, 2025, 4:00 PM EDT
1.849
+0.029 (1.60%)
After-hours: Oct 24, 2025, 7:59 PM EDT
RANI Revenue
Rani Therapeutics Holdings had revenue of $1.20M in the twelve months ending June 30, 2025. In the year 2024, Rani Therapeutics Holdings had annual revenue of $1.03M.
Revenue (ttm)
$1.20M
Revenue Growth
n/a
P/S Ratio
49.88
Revenue / Employee
$11,321
Employees
106
Market Cap
130.80M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.03M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 2.72M | 2.26M | 488.10% |
| Dec 31, 2020 | 462.00K | -517.00K | -52.81% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
RANI News
- 2 days ago - Rani Therapeutics Announces the Appointments of Abe Bassan and Vasudev Bailey, Ph.D. to Board of Directors - GlobeNewsWire
- 2 days ago - Rani Therapeutics Announces Closing of Oversubscribed $60.3 Million Private Placement Priced At-the-Market under Nasdaq Rules - GlobeNewsWire
- 6 days ago - Rani Therapeutics: Initiating At Buy On Promising RaniPill Advancement With Chugai - Seeking Alpha
- 6 days ago - CRMD, RANI, CELC, RAPT: four biotech stocks flying high today and why - Invezz
- 9 days ago - Rani Therapeutics signs up to $1.09 billion licensing deal with Japan's Chugai Pharma - Reuters
- 9 days ago - Rani Therapeutics Announces Oversubscribed $60.3 Million Private Placement Priced At-the-Market under Nasdaq Rules - GlobeNewsWire
- 9 days ago - Rani Therapeutics Announces up to $1.085 Billion Collaboration with Chugai Pharmaceutical Co. for Multiple High-Value Therapeutics Including Rare Disease and Immunology Programs and Announces Concurrent Oversubscribed $60.3 Million Financing - GlobeNewsWire
- 2 months ago - Rani Therapeutics Reports Second Quarter 2025 Financial Results; Provides Corporate Update - GlobeNewsWire